Market Currents
Achillion (ACHN +6.5%) discloses positive proof-of-concept results for ACH-3102 for treating...
-
Thursday, September 27, 2012, 8:37 AM ETAchillion (ACHN +6.5%) discloses positive proof-of-concept results for ACH-3102 for treating chronic hepatitis C viral infections (HCV). The company has now initiated a phase II study for the drug. Achillion is hosting an analyst day today, with a live Webcast beginning at 1:00 pm ET. (PR)
Other date
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles
